EDITORIAL
Managing risk of surgical procedures in pediatric transplant recipients taking mTOR inhibitors: What is the optimal strategy?
Kevin P. Daly,
Kevin P. Daly
Transplant Research Program, Boston Children's Hospital, Boston, MA, USA
Department of Cardiology, Boston Children's Hospital, Boston, MA, USA
Department of Pediatrics, Harvard Medical School, Boston, MA, USA
Search for more papers by this author
Kevin P. Daly,
Kevin P. Daly
Transplant Research Program, Boston Children's Hospital, Boston, MA, USA
Department of Cardiology, Boston Children's Hospital, Boston, MA, USA
Department of Pediatrics, Harvard Medical School, Boston, MA, USA
Search for more papers by this author
First published: 15 January 2018
No abstract is available for this article.
CONFLICT OF INTERESTS
The authors declare no conflict of interests.
REFERENCES
- 1Heble A, Everitt MD, Gralla J, Miyamoto SD, Lahart M, Eshelman J. Safety of mTOR inhibitor continuation in pediatric heart transplant recipients undergoing surgical procedures. Pediatr Transplant. 2018; 22: e13093.
- 2 Wyeth Pharmaceuticals Inc. RAPAMUNE(R) oral solution, oral tablets, sirolimus oral solution, oral tablets [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2013.
- 3Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation. 2004; 77: 1555-1561.
- 4Grim SA, Slover CM, Sankary H, Oberholzer J, Benedetti E, Clark NM. Risk factors for wound healing complications in sirolimus-treated renal transplant recipients. Transplant Proc. 2006; 38: 3520-3523.
- 5Zuckermann A, Arizon JM, Dong G, et al. Impact of de novo everolimus-based immunosuppression on incisional complications in heart transplantation. Transplantation. 2011; 92: 594-600.
- 6Schaffer M, Schier R, Napirei M, Michalski S, Traska T, Viebahn R. Sirolimus impairs wound healing. Langenbeck's Arch Surg. 2007; 392: 297-303.
- 7Bruneau S, Wedel J, Fakhouri F, et al. Translational implications of endothelial cell dysfunction in association with chronic allograft rejection. Pediatr Nephrol. 2016; 31: 41-51.
- 8Squarize CH, Castilho RM, Bugge TH, Gutkind JS. Accelerated wound healing by mTOR activation in genetically defined mouse models. PLoS One. 2010; 5: e10643.
